The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...

Novo Nordisk is currently leading the market for ... while CagriSema's top-line efficacy was in the same ballpark as Zepbound in the phase 3 readout. The new study showed that subcutaneous ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Only three drugs – Novo Nordisk’s Wegovy and Saxenda, and Eli Lilly’s Zepbound – are actually approved for that purpose. Now, if used correctly, these drugs can be a lifeline for patients.

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...

Welcome to the Relmada Therapeutics first-quarter 2025 earnings call. (Operator Instructions) As a reminder, this conference is being recorded, and will be available for replay on the location website ...